Editact Therapeutics showcased its latest advancements in developing the novel “one-for-many” genome editing therapy for Familial Alzheimer’s disease in HKUST Unicorn Day, held on 2 June, 2026.

HKUST Unicorn Day is recognised as a top event amongst the innovation and technology ecosystem in Hong Kong. Unicorn Day highlighted over 100 startup showcases, serving as a dynamic platform for knowledge exchange and collaboration.

Editact Therapeutics is dedicated to developing novel genome editing solutions for incurable diseases. With the support of the university and the HKSAR Innovation and Technology Commission, Editact is committed to advancing the lead candidate into clinical phase within the next 3 years.